Chien-Te Lee
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Chien-Te Lee has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
Jin-Bor Chen
3 shared publicationsChao-Cheng Huang
1 shared publication- How-Ran Guo
Department of Environmental and Occupational Health, College of Medicine, National Cheng Kung University
1 shared publication King Kuan Lam
Division of Nephrology Chang Gung Memorial Hospital Kaohsiung, Taiwan
1 shared publicationKing-Kwan Lam
1 shared publicationKuo-Tai Hsu
Division of Nephrology Chang Gung Memorial Hospital Kaohsiung, Taiwan
1 shared publication
Latest Publications
- 1 February 2001
- Published by S. Karger AG in American Journal of Nephrology
- Vol. 21 (1) , 47-50
Kimura’s Disease in a Chronic Hemodialysis Patient
Eosinophilia is not an uncommon finding in chronic dialysis patients. It is usually benign in nature although definite pathogenesis is unknown. We have encountered a young uremic Chinese adult who developed Kimura’s disease after being on maintenance hemodialysis for about 3 years. Asymptomatic eosinophilia had been noted for 1 year and 8 months prior to the development of progressively enlarged neck masses, which leads to the diagnosis of Kimura’s disease. In contrast to most cases, eosinophilia was first noticed before the neck masses appeared. There is often a close correlation between Kimura’s disease and glomerular disease, where renal involvement is considered as a systemic manifestation. However, we do not have strong evidence to support this relationship between terminal renal failure and Kimura’s disease in this patient. To our knowledge, our patient is the first reported case of Kimura’s disease occurring in chronic hemodialysis patients. Eosinophilia persisted for nearly 2 years before the neck mass developed and recurred after the excision. Besides, our patient also demonstrated a chronic and recurrent course typical of Kimura’s disease.
- 1 February 2001
- Published by S. Karger AG in American Journal of Nephrology
- Vol. 21 (1) , 47-50
Kimura’s Disease in a Chronic Hemodialysis Patient
Eosinophilia is not an uncommon finding in chronic dialysis patients. It is usually benign in nature although definite pathogenesis is unknown. We have encountered a young uremic Chinese adult who developed Kimura’s disease after being on maintenance hemodialysis for about 3 years. Asymptomatic eosinophilia had been noted for 1 year and 8 months prior to the development of progressively enlarged neck masses, which leads to the diagnosis of Kimura’s disease. In contrast to most cases, eosinophilia was first noticed before the neck masses appeared. There is often a close correlation between Kimura’s disease and glomerular disease, where renal involvement is considered as a systemic manifestation. However, we do not have strong evidence to support this relationship between terminal renal failure and Kimura’s disease in this patient. To our knowledge, our patient is the first reported case of Kimura’s disease occurring in chronic hemodialysis patients. Eosinophilia persisted for nearly 2 years before the neck mass developed and recurred after the excision. Besides, our patient also demonstrated a chronic and recurrent course typical of Kimura’s disease.
- 1 May 2000
- Published by Elsevier in The American Journal of Emergency Medicine
- Vol. 18 (3) , 264-268
Hyponatremia in the emergency department
- 1 May 2000
- Published by Elsevier in The American Journal of Emergency Medicine
- Vol. 18 (3) , 264-268
Hyponatremia in the emergency department
- 1 January 1999
- Published by Taylor & Francis in Renal Failure
- Vol. 21 (6) , 665-673
Low Dose Desferrioxamine Can Improve Erythropoiesis in Iron-Overload Hemodialysis Patients Without Side Effects
Objective: Multiple blood transfusions were often required to treat anemia in uremia patients before the era of recombinant human erythropoietin (r-HuEPO). Iron overload thus frequently occurred in chronic hemodialysis patients. Desferrioxamine (DFO) is an effective chelating agent, which can remove excessive iron and can enhance erythropoiesis. Large dose DFO treatment is a therapy associated with the development of severe complications. In this study, a low dose DFO regime was used to treat iron overloaded hemodialysis patients. The efficacy and side effects of this regiment were evaluated. Materials and Methods: Eight iron overloaded chronic hemodialysis patients were enrolled in this study. All patients received DFO 500 mg intravenously twice-a-week for eight months. Serum aluminum, transferrin saturation (TFS) and r-HuEPO requirement were recorded before and after DFO treatment. Serum ferritin and hematocrit (Hct) were measured before, during, and after the DFO withdrawal period. All patients were evaluated and followed closely during treatment. Results: Changes in aluminum, TFS and r-HuEPO dosage were unremarkable (p > 0.05). Hct increased significantly after eight months of DFO treatment (from 25.3% to 27.0%, p < 0.05), Ferritin level was reduced by 43.2% at the end of treatment and an evident decline of ferritin was achieved after four months of treatment (2102 ng/mL to 1166 ng/mL, p < 0.05). All patients tolerated the treatment well and no complications were found Conclusion: Low dose DFO can chelate iron effectively in chronic hemodialysis patients. This treatment can enhance erythropoiesis without adverse effects
- 1 January 1999
- Published by Taylor & Francis in Renal Failure
- Vol. 21 (6) , 665-673
Low Dose Desferrioxamine Can Improve Erythropoiesis in Iron-Overload Hemodialysis Patients Without Side Effects
Objective: Multiple blood transfusions were often required to treat anemia in uremia patients before the era of recombinant human erythropoietin (r-HuEPO). Iron overload thus frequently occurred in chronic hemodialysis patients. Desferrioxamine (DFO) is an effective chelating agent, which can remove excessive iron and can enhance erythropoiesis. Large dose DFO treatment is a therapy associated with the development of severe complications. In this study, a low dose DFO regime was used to treat iron overloaded hemodialysis patients. The efficacy and side effects of this regiment were evaluated. Materials and Methods: Eight iron overloaded chronic hemodialysis patients were enrolled in this study. All patients received DFO 500 mg intravenously twice-a-week for eight months. Serum aluminum, transferrin saturation (TFS) and r-HuEPO requirement were recorded before and after DFO treatment. Serum ferritin and hematocrit (Hct) were measured before, during, and after the DFO withdrawal period. All patients were evaluated and followed closely during treatment. Results: Changes in aluminum, TFS and r-HuEPO dosage were unremarkable (p > 0.05). Hct increased significantly after eight months of DFO treatment (from 25.3% to 27.0%, p < 0.05), Ferritin level was reduced by 43.2% at the end of treatment and an evident decline of ferritin was achieved after four months of treatment (2102 ng/mL to 1166 ng/mL, p < 0.05). All patients tolerated the treatment well and no complications were found Conclusion: Low dose DFO can chelate iron effectively in chronic hemodialysis patients. This treatment can enhance erythropoiesis without adverse effects